Ann: MD and CEO Dr Collier presents at BIO Asia T, page-3

re: Ann: MD and CEO Dr Collier presents at BI... Partnering is the only way forward for CPn10. From information available from the old management, it would take $5M just to have a production run for new drug. I would expect a similar amount to do meaningful trials. I can't see the market being happy with such a raise, particularly just after the last one. I totally support the present management approach. CPn10 is a depreciating asset. Our patents have a finite end date and every day we are not doing trials is money lost. What this asset needs is a large injection of cash to allow trials on a number of indications simultaneously so that we get maximum return before patents expire. Hopefully any potential partner will well understand this. Present management seem to.